##### Table of Contents



UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 WASHINGTON, DC 20549
 FORM 10-Q/A
 (Amendment No. 1)
 þ
    
    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2009
 or
 o
    
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 FOR THE TRANSITION PERIOD FROMTO
 Commission File Number: 001-33054
 TRUBION PHARMACEUTICALS, INC.
 (Exact name of registrant as specified in its charter)
 DELAWARE
(State or other jurisdiction of 
incorporation or organization)
    
    52-2385898
(IRS Employer Identification No.)2401 FOURTH AVENUE, SUITE 1050
SEATTLE, WASHINGTON
(Address of registrants principal 
executive offices)
    
    98121
(Zip Code)
 (206) 838-0500
(Telephone number, including area code)

N/A
(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)
 þ o
 o o
  Large accelerated filer
    
    Accelerated filer o
    
    Non-accelerated filer þ
(Do not check if a smaller reporting company)
    
    Smaller reporting company o
 o þ




---



TABLE OF CONTENTS  SIGNATURESEXHIBIT INDEXEX-10.1EX-31.3EX-31.4    Table of Contents  Explanatory Note




---



##### Table of Contents



SIGNATURES
   TRUBION PHARMACEUTICALS, INC.By:
    /s/ John A. BencichJohn A. BencichVice President and
Chief Financial Officer
(Principal Accounting and Financial Officer)




---



##### Table of Contents



EXHIBIT INDEX
 ExhibitNumber
    
    Description3.1
    
    Amended and Restated Certificate of Incorporation (Exhibit 3.1)(A)3.2
    
    Amended and Restated Bylaws (Exhibit 3.1)(B)4.1
    
    Form of common stock certificate (Exhibit 4.1)(C)4.2
    
    Amended and Restated Investor Rights Agreement, dated July 13, 2004 (Exhibit 4.2)(A)4.3
    
    Amendment No. 1 to Amended and Restated Investor Rights Agreement, dated December
19, 2005 (Exhibit 4.3)(A)10.1*
    
    Collaboration and License Agreement, dated August 27, 2009, by and between Facet
Biotech Corporation and Trubion Pharmaceuticals, Inc.10.2
    
    Manufacturing Services Agreement, dated November 21, 2005, by and between Lonza
Biologics and Trubion Pharmaceuticals, Inc. (Exhibit 10.37) (D)10.3
    
    Novation Agreement, effective as of January 1, 2007, among Trubion Pharmaceuticals,
Inc., Lonza Biologics, Inc. and Lonza Sales AG (Exhibit 10.3) (E)10.4
    
    Amendment, dated December 5, 2008, to the Manufacturing Services Agreement, dated
November 21, 2005, by and between Trubion Pharmaceuticals, Inc. and Lonza Sales AG
(Exhibit 10.4)(F)10.5
    
    Quality Agreement for TRU-016, dated December 5, 2008, by and between Trubion
Pharmaceuticals, Inc. and Lonza Sales AG (Exhibit 10.5)(F)10.6
    
    Second Amendment, dated April 3, 2009, to the Manufacturing Services Agreement,
dated November 21, 2005, by and between Trubion Pharmaceuticals, Inc.and Lonza
Sales AG (Exhibit 10.6)(F)31.1
    
    Certification of Chief Executive Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002 (Exhibit 31.1)(F)31.2
    
    Certification of Chief Financial Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002 (Exhibit 31.2)(F)31.3*
    
    Certification of Chief Executive Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 200231.4*
    
    Certification of Chief Financial Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 200232.1
    
    Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18
U.S.C § 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Exhibit 32.1)(F)
 
 (A)
    
    Incorporated by reference to the designated exhibit to the registrants
Registration Statement on Form S-1 filed with the SEC on June 2, 2006 (File No.
333-134709).(B)
    
    Incorporated by reference to the designated exhibit to the registrants Current
Report on Form 8-K filed with the SEC on November 26, 2008 (File No. 001-33054).(C)
    
    Incorporated by reference to the designated exhibit to the registrants
Registration Statement on Form S-1 filed with the SEC on October 2, 2006 (File No.
333-134709).(D)
    
    Incorporated by reference to the designated exhibit to the Registrants
Registration Statement on Form S-1 filed with the SEC on August 18, 2006.(E)
    
    Incorporated by reference to the designated exhibit to the Registrants quarterly
report on Form 10-Q filed with the SEC on August 7, 2008.(F)
    
    Incorporated by reference to the designated exhibit of the Registrants quarterly
report on Form 10-Q filed with the SEC on November 5, 2009.*
    
    Filed herewith.
    
    Portions of the agreement are subject to confidential treatment.